...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of health economics >Private versus social incentives for pharmaceutical innovation
【24h】

Private versus social incentives for pharmaceutical innovation

机译：药物创新的私人与社会激励

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We provide a theoretical framework to contribute to the current debate regarding-the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a model with a population of patients who can be treated with drugs that are horizontally and vertically differentiated. In addition to a pioneering drug, a new drug can be marketed as the result of an innovative process. We analyze physician prescription choices and the optimal pricing decision of an innovative firm. We also characterize the incentives of the innovative firm to conduct R&D activities, disentangling the quest for breakthrough drugs from the firm effort to develop follow-on drugs. Our results offer theoretical support for the conventional wisdom that pharmaceutical firms devote too many resources to conducting R&D activities that lead to incremental innovations. (C) 2016 Elsevier B.V. All rights reserved.
机译：我们提供了一个理论框架，可为当前有关以下问题的辩论做出贡献：制药公司倾向于将其研发方向推向已存在药物的“后续”药物营销产品，而不是针对突破性药物的开发。我们构建了一个可以用水平和垂直区分药物治疗的患者群体的模型。除了开创性的药物外，由于创新的方法，还可以销售新药。我们分析医师处方的选择和创新公司的最佳定价决策。我们还描述了创新公司进行研发活动的动机，将对突破性药物的追求与公司开发后续药物的努力区分开来。我们的结果为传统观点提供了理论支持，因为传统观点认为制药公司会投入太多资源进行研发活动，从而导致渐进式创新。 （C）2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号